RP105 deficiency attenuates early atherosclerosis via decreased monocyte influx in a CCR2 dependent manner

Atherosclerosis

Volumn 238, Issue 1, 2015, Pages 132-139

  Wezel, Anouk ^a,b   van der Velden, Daniël ^a,b   Maassen, Johanna M ^a   Lagraauw, H Maxime ^a   de Vries, Margreet R ^b   Karper, Jacco C ^b   Kuiper, Johan ^a   Bot, Ilze ^a,b   Quax, Paul H A ^b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; CCR2; Monocyte migration; RP105; TLR4

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR2; LOW DENSITY LIPOPROTEIN RECEPTOR; RADIOPROTECTIVE 105 PROTEIN; UNCLASSIFIED DRUG; CCR2 PROTEIN, MOUSE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN M; LEUKOCYTE ANTIGEN; LY78 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DOWN REGULATION; GENE DELETION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PERITONITIS; PROTEIN FOLDING; ANIMAL; ANIMAL FOOD; ATHEROSCLEROSIS; B LYMPHOCYTE; BLOOD; BONE MARROW; CELL MOTION; CROSS BREEDING; CYTOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMAL FEED; ANIMALS; ANTIGENS, CD; ATHEROSCLEROSIS; B-LYMPHOCYTES; BONE MARROW; CELL MOVEMENT; CROSSES, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOGLOBULIN E; IMMUNOGLOBULIN M; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; MONOCYTES; PERITONITIS; RECEPTORS, CCR2; RECEPTORS, LDL; SIGNAL TRANSDUCTION;

EID: 84914166645     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.11.020     Document Type: Article

References (38)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., Bravata D.M., Dai S., Ford E.S., Fox C.S., Fullerton H.J., Gillespie C., Hailpern S.M., Heit J.A., Howard V.J., Kissela B.M., Kittner S.J., Lackland D.T., Lichtman J.H., Lisabeth L.D., Makuc D.M., Marcus G.M., Marelli A., Matchar D.B., Moy C.S., Mozaffarian D., Mussolino M.E., Nichol G., Paynter N.P., Soliman E.Z., Sorlie P.D., Sotoodehnia N., Turan T.N., Virani S.S., Wong N.D., Woo D., Turner M.B. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220. American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
2. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N.Engl. J. Med. 2005, 352:1685-1695.
3. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu. Rev. Immunol. 2009, 27:165-197.
4. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 2011, 17:1410-1422.
5. Woollard K.J. Immunological aspects of atherosclerosis. Clin. Sci. Lond. 2013, 125:221-235.
6. Drechsler M., Soehnlein O. The complexity of arterial classical monocyte recruitment. J.Innate Immun. 2013, 5:358-366.
7. Hansson G.K., Libby P., Schönbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 2002, 91:281-291.
8. Bot I., Biessen E.A. Mast cells in atherosclerosis. Thromb. Haemost. 2011, 106:820-826.
9. Cole J.E., Georgiou E., Monaco C. The expression and functions of toll-like receptors in atherosclerosis. Mediat. Inflamm. 2010, 2010:393946.
10. Mann D.L. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ. Res. 2011, 108:1133-1145.
11. Ding Y., Subramanian S., Montes V.N., Goodspeed L., Wang S., Han C., Teresa A.S., Kim J., O'Brien K.D., Chait A. Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1596-1604.
12. Lu Z., Zhang X., Li Y., Jin J., Huang Y. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice. J.Endocrinol. 2013, 216:61-71.
13. Divanovic S., Trompette A., Petiniot L.K., Allen J.L., Flick L.M., Belkaid Y., Madan R., Haky J.J., Karp C.L. Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105. J.Leukoc. Biol. 2007, 82:265-271.
14. Akashi-Takamura S., Miyake K. TLR accessory molecules. Curr. Opin. Immunol. 2008, 20:420-425.
15. Divanovic S., Trompette A., Atabani S.F., Madan R., Golenbock D.T., Visintin A., Finberg R.W., Tarakhovsky A., Vogel S.N., Belkaid Y., Kurt-Jones E.A., Karp C.L. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat. Immunol. 2005, 6:571-578.
16. Yoon S.I., Hong M., Wilson I.A. An unusual dimeric structure and assembly for TLR4 regulator RP105-MD-1. Nat. Struct. Mol. Biol. 2011, 18:1028-1035.
17. Ohto U., Miyake K., Shimizu T. Crystal structures of mouse and human RP105/MD-1 complexes reveal unique dimer organization of the toll-like receptor family. J.Mol. Biol. 2011, 413:815-825.
18. Karper J.C., de Jager S.C., Ewing M.M., de Vries M.R., Bot I., van Santbrink P.J., Redeker A., Mallat Z., Binder C.J., Arens R., Jukema J.W., Kuiper J., Quax P.H. An unexpected intriguing effect of Toll-like receptor regulator RP105 (CD180) on atherosclerosis formation with alterations on B-cell activation. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2810-2817.
19. Karper J.C., Ewing M.M., de Vries M.R., de Jager S.C., Peters E.A., de Boer H.C., van Zonneveld A.J., Kuiper J., Huizinga E.G., Brondijk T.H., Jukema J.W., Quax P.H. TLR accessory molecule RP105 (CD180) is involved in post-interventional vascular remodeling and soluble RP105 modulates neointima formation. PLoS One 2013, 8:e67923.
20. von der Thüsen J.H., van Berkel T.J., Biessen E.A. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001, 103:1164-1170.
21. Miyake K., Yamashita Y., Ogata M., Sudo T., Kimoto M. RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family. J.Immunol. 1995, 154:3333-3340.
22. Francke A., Herold J., Weinert S., Strasser R.H., Braun-Dullaeus R.C. Generation of mature murine monocytes from heterogeneous bone marrow and description of their properties. J.Histochem. Cytochem. 2011, 59:813-825.
23. Ogata H., Su I., Miyake K., Nagai Y., Akashi S., Mecklenbräuker I., Rajewsky K., Kimoto M., Tarakhovsky A. The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J.Exp. Med. 2000, 192:23-29.
24. Eefting D., Bot I., de Vries M.R., Schepers A., van Bockel J.H., Van Berkel T.J., Biessen E.A., Quax P.H. Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice. J.Vasc. Surg. 2009, 50:152-160.
25. Bot I., Guo J., Van Eck M., Van Santbrink P.J., Groot P.H., Hildebrand R.B., Seppen J., Van Berkel T.J., Biessen E.A. Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown ofCCR2 function invivo. Blood 2005, 106:1147-1153.
26. Campbell K.A., Lipinski M.J., Doran A.C., Skaflen M.D., Fuster V., McNamara C.A. Lymphocytes and the adventitial immune response in atherosclerosis. Circ. Res. 2012, 110:889-900.
27. Tsiantoulas D., Diehl C.J., Witztum J.L., Binder C.J. Bcells and humoral immunity in atherosclerosis. Circ. Res. 2014, 114:1743-1756.
28. Stoneman V., Braganza D., Figg N., Mercer J., Lang R., Goddard M., Bennett M. Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ. Res. 2007, 100:884-893.
29. Bastiaansen A.J., Karper J.C., Wezel A., de Boer H.C., Welten S.M., de Jong R.C., Peters E.A., de Vries M.R., van Oeveren-Rietdijk A.M., van Zonneveld A.J., Hamming J.F., Nossent A.Y., Quax P.H. TLR4 accessory molecule RP105 (CD180) regulates monocyte-driven arteriogenesis in a murine hind limb ischemia model. PLoS One 2014, 9:e99882.
30. Strauss-Ayali D., Conrad S.M., Mosser D.M. Monocyte subpopulations and their differentiation patterns during infection. J.Leukoc. Biol. 2007, 82:244-252.
31. Boring L., Gosling J., Cleary M., Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897.
32. Dawson T.C., Kuziel W.A., Osahar T.A., Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 1999, 143:205-211.
33. Yi L., Chandrasekaran P., Venkatesan S. TLR signaling paralyzes monocyte chemotaxis through synergized effects of p38 MAPK and global Rap-1 activation. PLoS One 2012, 7:e30404.
34. Xu L., Khandaker M.H., Barlic J., Ran L., Borja M.L., Madrenas J., Rahimpour R., Chen K., Mitchell G., Tan C.M., DeVries M., Feldman R.D., Kelvin D.J. Identification of a novel mechanism for endotoxin-mediated down-modulation of CC chemokine receptor expression. Eur. J. Immunol. 2000, 30:227-235.
35. Heesen M., Renckens R., de Vos A.F., Kunz D., van der Poll T. Human endotoxemia induces down-regulation of monocyte CC chemokine receptor 2. Clin. Vaccine Immunol. 2006, 13:156-159.
36. Parker L.C., Whyte M.K., Vogel S.N., Dower S.K., Sabroe I. Toll-like receptor (TLR)2 and TLR4 agonists regulate CCR expression in human monocytic cells. J.Immunol. 2004, 172:4977-4986.
37. Divanovic S., Trompette A., Atabani S.F., Madan R., Golenbock D.T., Visintin A., Finberg R.W., Tarakhovsky A., Vogel S.N., Belkaid Y., Kurt-Jones E.A., Karp C.L. Inhibition of TLR4/MD-2 signaling by RP105/MD-1. J.Endotoxin Res. 2005, 11:363-368.
38. Moore K.J., Sheedy F.J., Fisher E.A. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 2013, 13:709-721.